Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2014 William Looney	IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Chemistry World February 12, 2015 S Umapathy	Indian science at the crossroads How should Indian scientific research evolve?
Pharmaceutical Executive August 1, 2012	Piramal Pivots for Growth Western drug makers face an unlikely challenge from India's Piramal Healthcare, which has divested its big stake in branded generics for the risky embrace of new drug innovation.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive August 1, 2011 William Looney	Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation.
Pharmaceutical Executive April 1, 2011	How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry.
Pharmaceutical Executive March 1, 2014 William Looney	The Call to Community: A Conversation with Dr. David Nash Population health is the foundation for much of what is truly new in US health reform. For big Pharma, it represents yet another escalation in expectations.
Pharmaceutical Executive April 1, 2014 William Looney	The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines.
Chemistry World March 6, 2015 Sanjay Kumar	Scientists left unimpressed by Indian budget The Indian government's 'big-bang' budget has left the country's science community sorely disappointed.
Pharmaceutical Executive June 1, 2011	2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead.
Pharmaceutical Executive August 1, 2012 Pascheles & Bogan	The Ultimate Business Model: Planning that Thousand Year Future In an era where success is monitored and measured in microseconds, planning for the long term is increasingly seen as an abstract absurdity. Yet the principles of natural selection, when applied to the pharmaceutical business, suggest that a lasting business model is still possible.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Pharmaceutical Executive October 1, 2011	Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
Chemistry World August 14, 2015 Jennifer Newton	No one should be denied medication 'My whole fight today, for the third world, is for access to medicine at affordable prices,' attests Indian generics manufacturer Cipla chairman Yusuf Hamied.
Chemistry World September 17, 2010 Andrew Turley	Free trade could throttle generics from India International agreements on intellectual property threaten the flow of generic HIV drugs from India to developing countries, according to a new report.
Pharmaceutical Executive January 1, 2013 William Looney	The Permanent Campaign Promoting the merits of private-sector drug innovation is no easy task; just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Pharmaceutical Executive July 3, 2007	Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future.
Chemistry World October 8, 2010 Akshat Rathi	India calls for ambitious increase in science funding The Scientific Advisory Council to the Prime Minister of India has advised the government to increase its science funding from less than 1 per cent of GDP to up to 2.5 per cent by 2020.
Finance & Development June 1, 2006 Raymond Lim	Creating a Globally Connected Asian Community As Asia connects to the world, there is every reason to hope that the same principle and structure of a community based on complementary growth and positive competition, held together by overlapping political and economic relationships, can serve as a model for the rest of the world.
Chemistry World March 20, 2012 Rajesh Parishwad	India Green Lights Production of Patented Cancer Drug For the first time India has invoked a 'compulsory license' clause to cut the cost of a patented anti-cancer drug by allowing another company to manufacture the therapy.
Pharmaceutical Executive April 1, 2012 William Looney	IP: Time for a Reset? Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.
Pharmaceutical Executive August 1, 2012	Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
Knowledge@Wharton	Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy."
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Global Services November 4, 2008 Jolie Newman	The Innovation Imperative Understand the essential nature of innovation in outsourcing engagements.
Chemistry World February 13, 2012	Building a nation of scientists Goverdhan Mehta talks to Sheena Elliott and Elinor Richards about the progress of science in India and the challenges scientists face
HBS Working Knowledge June 21, 2010 Martha Lagace	Strategy and Execution for Emerging Markets The ambition level of large, fast-growing emerging markets around the world rivals that of companies in the United States in the late 19th and early 20th centuries. Here's how to identify and respond to institutional voids in product, labor, and capital markets.
Pharmaceutical Executive October 1, 2011 Amrita Ghaswalla	Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied.
Chemistry World January 14, 2013 Rajesh Parishwad	India sets ambitious targets for science India's prime minister Manmohan Singh wants the country to be one of the world's top 5 scientific powers by 2020
CIO September 14, 2012 Kim S. Nash	Innovation Can Start Far From Home The needs of customers in emerging markets are far different than those of customers in the rich world. Innovations needed to meet the needs of customers in the developing world can flow uphill.
Pharmaceutical Executive September 1, 2012 Thomas Baker	The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support.
Pharmaceutical Executive April 1, 2006 Christensen, McLaughlin & Wunker	The Road to Nowhere? More effective drugs? Another dead end. But patients open their wallets when a "good enough" drug gets better.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Pharmaceutical Executive November 1, 2014 William Looney	Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.
IndustryWeek December 1, 2008 Adrienne Selko	The Rise Of Indian Manufacturing As India's production capabilities increase, U.S. manufacturers would do well to craft a global strategy that addresses the emergence of this no-longer-slumbering giant.
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
HBS Working Knowledge November 20, 2006 Martha Lagace	Open Source Science: A New Model for Innovation Practices in the open source software community offer a model for encouraging large-scale scientific problem solving.
Pharmaceutical Executive January 1, 2012 William Looney	The Well of Engagement We sometimes forget that the business of healthcare is also the source of a huge opportunity: improving the human condition.
Pharmaceutical Executive July 10, 2014 William Looney	Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead.
Chemistry World February 3, 2015 Sanjay Kumar	India's chemistry challenges While India is yet to catch up with the global cutting edge technologies, some of its interventions have made global headlines.
Pharmaceutical Executive October 1, 2005 Fine & Meyer	An 11-Step Program to Navigating Partnerships Commercial partnerships are an effective way to differentiate both research institutes and biotech companies. It is critical to recognize that while financial return is the primary driver of a commercial partnership, the cultural fit can sustain its success.
Pharmaceutical Executive September 1, 2012 Roy F. Waldron	Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector?
Pharmaceutical Executive August 1, 2013 William Looney	Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate.
IEEE Spectrum November 2008 Hira & Ross	R&D Goes Global Hidden in corporate research budgets is a shift of R&D work to low-cost countries, particularly China and India.
IndustryWeek February 17, 2010 Joachim Ebert	Driving Growth Through Ultra-Low-Cost Product Development For both emerging and developed markets, ultra-low-cost products are here to stay and offer rich rewards for companies that can follow these 10 imperatives for success.